Hepatocyte growth factor and alternative splice variants - expression, regulation and implications in osteogenesis and bone health and repair

Rachel N. Frisch, Kevin M. Curtis, Kristina K. Aenlle, Guy Howard

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction: Bone marrow-derived mesenchymal stem cells (MSCs) can differentiate into multiple cell types, including osteoblasts, chondrocytes, and adipocytes. These pluripotent cells secrete hepatocyte growth factor (HGF), which regulates cell growth, survival, motility, migration, mitogenesis and is important for tissue development/regeneration. HGF has four splice variants, NK1, NK2, NK3, and NK4 which have varying functions and affinities for the HGF receptor, cMET. HGF promotes osteoblastic differentiation of MSCs into bone forming cells, playing a role in bone development, health and repair. Areas Covered: This review will focus on the effects of HGF in osteogenesis, bone repair and bone health, including structural and functional insights into the role of HGF in the body. Expert Opinion: Approximately 6.2 million Americans experience a fracture annually, with 5-10% being mal- or non-union fractures. HGF is important in priming MSCs for osteogenic differentiation in vitro and is currently being studied to assess its role during bone repair in vivo. Due to the high turnover rate of systemic HGF, non-classic modes of HGF-treatment, including naked-plasmid HGF delivery and the use of HGF splice variants (NK1 & NK2) are being studied to find safe and efficacious treatments for bone disorders, such as mal- or non-union fractures.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalExpert Opinion on Therapeutic Targets
DOIs
StateAccepted/In press - Mar 21 2016

Fingerprint

Hepatocyte Growth Factor
Osteogenesis
Bone
Repair
Health
Bone and Bones
Stem cells
Mesenchymal Stromal Cells
Proto-Oncogene Proteins c-met
Bone Development
Osteoblasts
Expert Testimony
Cell growth
Chondrocytes
Adipocytes
Regeneration
Cell Differentiation
Cell Survival
Plasmids
Bone Marrow

Keywords

  • Bone
  • cMET
  • Hepatocyte Growth Factor
  • HGF
  • Osteoblastic Differentiation
  • Osteoblasts
  • Osteoclasts

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Hepatocyte growth factor and alternative splice variants - expression, regulation and implications in osteogenesis and bone health and repair. / Frisch, Rachel N.; Curtis, Kevin M.; Aenlle, Kristina K.; Howard, Guy.

In: Expert Opinion on Therapeutic Targets, 21.03.2016, p. 1-12.

Research output: Contribution to journalArticle

@article{2467ace23185404e94180b4ecb990878,
title = "Hepatocyte growth factor and alternative splice variants - expression, regulation and implications in osteogenesis and bone health and repair",
abstract = "Introduction: Bone marrow-derived mesenchymal stem cells (MSCs) can differentiate into multiple cell types, including osteoblasts, chondrocytes, and adipocytes. These pluripotent cells secrete hepatocyte growth factor (HGF), which regulates cell growth, survival, motility, migration, mitogenesis and is important for tissue development/regeneration. HGF has four splice variants, NK1, NK2, NK3, and NK4 which have varying functions and affinities for the HGF receptor, cMET. HGF promotes osteoblastic differentiation of MSCs into bone forming cells, playing a role in bone development, health and repair. Areas Covered: This review will focus on the effects of HGF in osteogenesis, bone repair and bone health, including structural and functional insights into the role of HGF in the body. Expert Opinion: Approximately 6.2 million Americans experience a fracture annually, with 5-10{\%} being mal- or non-union fractures. HGF is important in priming MSCs for osteogenic differentiation in vitro and is currently being studied to assess its role during bone repair in vivo. Due to the high turnover rate of systemic HGF, non-classic modes of HGF-treatment, including naked-plasmid HGF delivery and the use of HGF splice variants (NK1 & NK2) are being studied to find safe and efficacious treatments for bone disorders, such as mal- or non-union fractures.",
keywords = "Bone, cMET, Hepatocyte Growth Factor, HGF, Osteoblastic Differentiation, Osteoblasts, Osteoclasts",
author = "Frisch, {Rachel N.} and Curtis, {Kevin M.} and Aenlle, {Kristina K.} and Guy Howard",
year = "2016",
month = "3",
day = "21",
doi = "10.1517/14728222.2016.1162293",
language = "English (US)",
pages = "1--12",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Hepatocyte growth factor and alternative splice variants - expression, regulation and implications in osteogenesis and bone health and repair

AU - Frisch, Rachel N.

AU - Curtis, Kevin M.

AU - Aenlle, Kristina K.

AU - Howard, Guy

PY - 2016/3/21

Y1 - 2016/3/21

N2 - Introduction: Bone marrow-derived mesenchymal stem cells (MSCs) can differentiate into multiple cell types, including osteoblasts, chondrocytes, and adipocytes. These pluripotent cells secrete hepatocyte growth factor (HGF), which regulates cell growth, survival, motility, migration, mitogenesis and is important for tissue development/regeneration. HGF has four splice variants, NK1, NK2, NK3, and NK4 which have varying functions and affinities for the HGF receptor, cMET. HGF promotes osteoblastic differentiation of MSCs into bone forming cells, playing a role in bone development, health and repair. Areas Covered: This review will focus on the effects of HGF in osteogenesis, bone repair and bone health, including structural and functional insights into the role of HGF in the body. Expert Opinion: Approximately 6.2 million Americans experience a fracture annually, with 5-10% being mal- or non-union fractures. HGF is important in priming MSCs for osteogenic differentiation in vitro and is currently being studied to assess its role during bone repair in vivo. Due to the high turnover rate of systemic HGF, non-classic modes of HGF-treatment, including naked-plasmid HGF delivery and the use of HGF splice variants (NK1 & NK2) are being studied to find safe and efficacious treatments for bone disorders, such as mal- or non-union fractures.

AB - Introduction: Bone marrow-derived mesenchymal stem cells (MSCs) can differentiate into multiple cell types, including osteoblasts, chondrocytes, and adipocytes. These pluripotent cells secrete hepatocyte growth factor (HGF), which regulates cell growth, survival, motility, migration, mitogenesis and is important for tissue development/regeneration. HGF has four splice variants, NK1, NK2, NK3, and NK4 which have varying functions and affinities for the HGF receptor, cMET. HGF promotes osteoblastic differentiation of MSCs into bone forming cells, playing a role in bone development, health and repair. Areas Covered: This review will focus on the effects of HGF in osteogenesis, bone repair and bone health, including structural and functional insights into the role of HGF in the body. Expert Opinion: Approximately 6.2 million Americans experience a fracture annually, with 5-10% being mal- or non-union fractures. HGF is important in priming MSCs for osteogenic differentiation in vitro and is currently being studied to assess its role during bone repair in vivo. Due to the high turnover rate of systemic HGF, non-classic modes of HGF-treatment, including naked-plasmid HGF delivery and the use of HGF splice variants (NK1 & NK2) are being studied to find safe and efficacious treatments for bone disorders, such as mal- or non-union fractures.

KW - Bone

KW - cMET

KW - Hepatocyte Growth Factor

KW - HGF

KW - Osteoblastic Differentiation

KW - Osteoblasts

KW - Osteoclasts

UR - http://www.scopus.com/inward/record.url?scp=84961393872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961393872&partnerID=8YFLogxK

U2 - 10.1517/14728222.2016.1162293

DO - 10.1517/14728222.2016.1162293

M3 - Article

C2 - 26941128

AN - SCOPUS:84961393872

SP - 1

EP - 12

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

ER -